An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials

MLA

Bringhen, Sara, et al. “An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials.” Blood, vol. 128, no. 22, Dec. 2016, p. 3336. EBSCOhost, https://doi.org/10.1182/blood.V128.22.3336.3336.

APA

Bringhen, S., Petrucci, M. T., Giuliani, N., Carella, A. M., Genuardi, M., Caravita di Toritto, T., Malfitano, A., Musto, P., Ria, R., Ciccone, G., Omedé, P., Offidani, M., Musolino, C., Liberati, A. M., De Paoli, L., Ballanti, S., Galieni, P., Cavo, M., Conticello, C., … Boccadoro, M. (2016). An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials. Blood, 128(22), 3336. https://doi.org/10.1182/blood.V128.22.3336.3336

Chicago

Bringhen, Sara, Maria Teresa Petrucci, Nicola Giuliani, Angelo Michele Carella, Mariella Genuardi, Tommaso Caravita di Toritto, Alessandra Malfitano, et al. 2016. “An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials.” Blood 128 (22): 3336. doi:10.1182/blood.V128.22.3336.3336.